teduglutide (Gattex)

Peptide

Also known as ALX-0600

Approvedregulatory verdict

Evidence outlook

Approved: Short Bowel Syndrome

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Treatment of short bowel syndrome
Product first approved 2021PMDA
EU
  • Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
Product first approved 2012EMA

Development in Crohn's Disease stopped (2009) as a strategic decision by the sponsor. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (18)
Short Bowel Syndrome
NCT06973304 · Takeda
2025-06-26 – 2027-07-28 · Short Bowel Syndrome
What this study did
NCT05027308 · Takeda
2022-01-04 – 2023-09-27 · Short Bowel Syndrome
What this study did
NCT03268811 · Shire
2017-08-23 – 2021-11-02 · Short Bowel Syndrome
What this study did
NCT03571516 · Shire
2018-08-31 – 2020-09-24 · Short Bowel Syndrome
What this study did
NCT02949362 · Shire
2016-12-09 – 2020-07-14 · Short Bowel Syndrome
What this study did
NCT02980666 · Shire
2017-01-13 – 2020-01-21 · Short Bowel Syndrome
What this study did
NCT03663582 · Shire
2018-07-06 – 2019-08-06 · Short Bowel Syndrome
What this study did
NCT02340819 · Shire
2014-12-18 – 2018-11-05 · Short Bowel Syndrome
What this study did
NCT01952080 · Shire
2013-11-14 – 2015-01-09 · Short Bowel Syndrome
What this study did
NCT01560403 · Shire
2012-05-21 – 2013-07-23 · Short Bowel Syndrome
What this study did
Other / comorbidity
NCT03953170 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
2022-06-02 – 2022-12-29 · Ileostomy - Stoma
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT03422666 · University Health Network, Toronto
2018-09-21 – 2021-12-01 · Hyperlipidemias
What this study did
NCT03442972 · University Health Network, Toronto
2019-01-17 – 2021-12-01 · Hyperlipidemias
What this study did
NCT03534661 · University Health Network, Toronto
2017-09-27 – 2019-03-20 · Hyperlipidemias
What this study did
Phase 2 (6)
Other / comorbidity
NCT07537686 · International Centre for Diarrhoeal Disease Research, Bangladesh
2026-07-01 – 2027-12-30 · Environmental Enteric Dysfunction
What this study did
NCT02889393 · Daniel Dante Yeh
2019-01-31 – 2021-07-15 · Postoperative Fistula
What this study did
NCT03716115 · Queen Mary University of London
2020-05-04 – 2021-04-27 · Severe Acute Malnutrition
What this study did
NCT02431325 · Massachusetts General Hospital
2015-12 – 2021-01-21 · HIV
What this study did
NCT00308438 · Shire
2004-03-01 – 2006-06-01 · Crohn's Disease
What this study did
NCT00072839 · Shire
2003-11-12 – 2005-07-28 · Crohn's Disease
What this study did
Phase 1 (7)
Other / comorbidity
NCT04290429 · University of Freiburg
2017-12-06 – 2019-12-06 · Graft Versus Host Disease
What this study did
NCT01209351 · Shire
2010-09-28 – 2010-11-08 · Healthy Volunteers
What this study did
NCT01028924 · Nycomed
2009-11 – 2010-04 · Healthy
What this study did
NCT01028768 · Nycomed
2009-10 – 2010-03 · Renal Impairment
What this study did
NCT00819468 · Shire
2007-07-26 – 2007-08-23 · Hepatic Impairment
What this study did
NCT00820885 · Shire
2006-09-06 – 2007-04-23 · Pharmacokinetics and Safety of Elevated Doses
What this study did
Phase 4 (2)
Short Bowel Syndrome
NCT03562130 · Assistance Publique - Hôpitaux de Paris
2018-07-02 – 2020-07-13 · Short Bowel Syndrome
What this study did
NCT02099084 · Mayo Clinic
2014-01 – 2015-03 · Short Bowel Syndrome
What this study did
Early phase / not applicable (1)
Short Bowel Syndrome
NCT07400783 · Meyer Children's Hospital IRCCS
2024-10-30 – 2027-02 · Short Bowel Syndrome (SBS)
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Short Bowel Syndrome: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Teduglutide (Gattex): this drugApprovedPeptideGLP-2 receptorPartial signal
NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants
NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects
ApraglutidePhase 3PeptideGLP-2 receptornot yet gradedNo reviewed efficacy summary in this indication
Crofelemer (Mytesi)Phase 2Small moleculeChloride channel (intestinal epithelium)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow teduglutide (Gattex) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Early phase / not applicableShort Bowel SyndromeRecruiting
Est. primary completion 2027-01 · NCT07400783 · CT.gov ↗
What to watch
February 2027 (1)
Phase 3Short Bowel SyndromeActive not recruiting
Est. primary completion 2027-02-10 · NCT06973304 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Environmental Enteric DysfunctionNot yet recruiting
Est. primary completion 2027-10-01 · NCT07537686 · CT.gov ↗
What to watch

See the full readout calendar ↗